Innovation Pharmaceuticals Inc. (IPIX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Innovation Pharmaceuticals Inc. (IPIX) trades at $0.00 with AI Score 39/100 (Grade D). Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for various medical conditions. Market cap: $155,504, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for IPIX: IPIX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IPIX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IPIX: 1/1 perspectives are bearish.
How is this calculated? →Innovation Pharmaceuticals Inc. (IPIX) Healthcare & Pipeline Overview
Innovation Pharmaceuticals Inc. specializes in developing innovative small molecule therapies, with a focus on addressing unmet medical needs in inflammatory diseases, cancer, and infectious conditions, positioning itself as a key player in the biotechnology sector.
What Is the Investment Thesis for IPIX?
Innovation Pharmaceuticals Inc. presents a unique investment thesis driven by its promising pipeline of drug candidates, particularly Brilacidin, which is currently in various stages of clinical trials. The company’s focus on multiple therapeutic areas, including oncology and infectious diseases, positions it to capitalize on significant market opportunities. As the clinical trials progress, successful outcomes could lead to potential partnerships or acquisitions, enhancing the company’s valuation. Furthermore, the biopharmaceutical sector is expected to grow, with the global biotechnology market projected to reach $727.1 billion by 2025, driven by advancements in drug development and increasing healthcare demands. However, investors should be mindful of the inherent risks associated with clinical-stage companies, including regulatory hurdles and the uncertainty of trial outcomes.
Based on FMP financials and quantitative analysis
IPIX Key Highlights
- Market Cap: $0.00B, indicating a nascent stage in market presence.
- Beta: -0.49, suggesting lower volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment in R&D.
- Small team of 4 employees, emphasizing a lean operational structure.
- Strong pipeline with Brilacidin as a lead candidate targeting multiple indications.
Who Are IPIX's Competitors?
IPIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMRN Amarin Corporation plc | $15.66 | -4.34% | $323.89M | 51 |
| NDAQ Nasdaq, Inc. | $85.28 | +0.73% | $48.23B | 68 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IPIX's Key Strengths?
- Innovative pipeline with lead candidate Brilacidin targeting multiple diseases.
- Strong focus on small molecule therapies addressing significant medical needs.
- Established partnerships that enhance research and development capabilities.
What Are IPIX's Weaknesses?
- Limited operational scale with only 4 employees.
- Dependence on successful clinical trial outcomes for future growth.
- No current revenue stream, relying on external funding.
What Could Drive IPIX Stock Higher?
- Results from ongoing clinical trials for Brilacidin expected in Q4 2026.
- Collaboration with Alfasigma S.p.A. to enhance drug development efforts.
- Research partnership with Fox Chase Chemical Diversity Center, Inc. to advance therapeutic candidates.
What Are the Key Risks for IPIX?
- Financial-distress signal — its Altman Z-Score of -28.49 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-93.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory approval delays could hinder the commercialization of drug candidates.
- Market competition from larger biotechnology firms may impact growth.
- Clinical trial failures could lead to significant financial setbacks.
What Are the Growth Opportunities for IPIX?
- Expansion of Brilacidin's clinical applications: Brilacidin is currently being investigated for multiple indications, including oral mucositis and COVID-19. The global market for oral mucositis treatments is projected to reach $1.2 billion by 2027, driven by an increasing incidence of cancer treatments that lead to this condition. Successful clinical outcomes could position Innovation Pharmaceuticals to capture a significant share of this market by 2027.
- Advancement of Kevetrin in oncology: Kevetrin is being researched for its potential in treating ovarian cancer, a market valued at approximately $4.5 billion in 2020 and expected to grow significantly. The increasing prevalence of ovarian cancer and the demand for effective treatments present a substantial growth opportunity for Innovation Pharmaceuticals as they advance Kevetrin through clinical trials over the next few years.
- Strategic partnerships and collaborations: The existing license agreement with Alfasigma S.p.A. and research collaboration with Fox Chase Chemical Diversity Center, Inc. provide Innovation Pharmaceuticals with enhanced research capabilities and market access. Further strategic partnerships could facilitate accelerated drug development and commercialization, potentially leading to increased revenue streams as products reach the market.
- Geographic market expansion: Innovation Pharmaceuticals has the potential to expand its market presence beyond the U.S., targeting international markets where there is a high demand for innovative therapies. The global biopharmaceutical market is expected to grow, providing opportunities for companies like Innovation Pharmaceuticals to leverage their drug candidates in new regions, particularly in Europe and Asia.
- Focus on rare diseases: The company’s focus on developing therapies for rare and underserved conditions aligns with current market trends favoring orphan drugs. The global market for orphan drugs is expected to exceed $200 billion by 2025, presenting a lucrative opportunity for Innovation Pharmaceuticals to develop niche therapies that meet critical healthcare needs.
What Opportunities Does IPIX Have?
- Expansion into international markets for drug candidates.
- Growing demand for orphan drugs and therapies for rare diseases.
- Potential for strategic partnerships to expedite drug development.
What Threats Does IPIX Face?
- Regulatory hurdles and challenges in obtaining FDA approvals.
- High competition in the biotechnology sector from larger firms.
- Market volatility impacting funding and investment opportunities.
What Are IPIX's Competitive Advantages?
- Innovative drug candidates with potential for multiple indications.
- Strategic partnerships that enhance research capabilities and market access.
- Focus on rare and underserved medical conditions with high unmet needs.
- Small operational footprint allowing for agile decision-making and resource allocation.
What Does IPIX Do?
Innovation Pharmaceuticals Inc., founded in 2005 and headquartered in Wakefield, Massachusetts, operates as a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Initially known as Cellceutix Corporation, the company rebranded to its current name in June 2017 to better reflect its focus on innovation in pharmaceuticals. The company's pipeline includes a diverse range of therapeutic areas, specifically targeting inflammatory diseases, cancer, dermatology, and infectious conditions. Its lead drug candidate, Brilacidin, is currently undergoing clinical trials for several indications, including oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infections, and COVID-19. Additionally, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound that is being investigated for its potential in treating ovarian cancer. The company has established strategic partnerships, including a license agreement with Alfasigma S.p.A. and a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc., which enhance its research capabilities and market reach. With a small team of four employees, Innovation Pharmaceuticals is focused on leveraging its innovative drug candidates to address significant medical needs and improve patient outcomes.
What Products and Services Does IPIX Offer?
- Develops small molecule therapies for various medical conditions.
- Focuses on clinical-stage drug development in oncology and infectious diseases.
- Conducts research and clinical trials to validate drug efficacy and safety.
- Collaborates with strategic partners to enhance research capabilities.
- Targets unmet medical needs in inflammatory diseases and cancer.
- Operates with a lean team to maximize resource efficiency.
How Does IPIX Make Money?
- Generates revenue through potential partnerships and licensing agreements.
- Focuses on advancing drug candidates through clinical trials to attract investment.
- Seeks to commercialize successful therapies to address market needs.
- Utilizes strategic collaborations to enhance research and development efforts.
- Aims to secure funding through grants and public offerings as drug candidates progress.
What Industry Does IPIX Operate In?
The biotechnology industry is characterized by rapid innovation and significant growth potential, driven by advancements in drug discovery and increasing demand for novel therapies. The global biotechnology market is projected to grow at a CAGR of approximately 7.4%, reaching $727.1 billion by 2025. Innovation Pharmaceuticals Inc. operates within this dynamic landscape, focusing on small molecule therapies that address unmet medical needs in various therapeutic areas. The competitive landscape includes numerous players, but Innovation Pharmaceuticals differentiates itself through its targeted approach and innovative drug candidates, particularly Brilacidin and Kevetrin.
Who Are IPIX's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from inflammatory diseases and cancer.
- Pharmaceutical partners interested in licensing or collaboration.
- Research institutions conducting clinical trials and studies.
- Investors looking for opportunities in the biopharmaceutical sector.
Company Profile
Innovation Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wakefield, US. The company is led by CEO Leo Ehrlich. IPIX has traded publicly since 2007.
F-Score 2/9Financial Health
Innovation Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.49 places it in the distress zone, a signal of elevated financial risk.
ROE -94%Key Financial Metrics
Return on equity for Innovation Pharmaceuticals Inc. stands at -93.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.1%, showing how much profit it generates from its asset base. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching.
IPIX Valuation & Market Position
With a 156K market cap, Innovation Pharmaceuticals Inc. sits in the micro-cap segment of the market. Relative to its peer group, IPIX's quantitative score of 39/100 is below the peer average of 71/100.
IPIX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential.
- Community sentiment has shown increasing optimism, with discussions highlighting the company's innovative drug pipeline and recent clinical developments.
- Market perception has been bolstered by positive news coverage, emphasizing the potential impact of their therapies on significant health issues.
- The overall sentiment in biotech has shifted positively, with investors looking for the next breakthrough, positioning IPIX favorably within that context.
Bear Case
- Concerns about the company's financial health persist, with ongoing discussions around funding and cash flow management raising red flags among investors.
- The recent volatility in biotech stocks has led to cautious sentiment, with some community members expressing skepticism about IPIX's ability to deliver on its promises.
- Insider selling activity has been noted, which can often signal a lack of confidence in the company's short-term performance or outlook.
- There are lingering doubts about the competitive landscape in the biotech sector, with some believing that IPIX may struggle to differentiate itself from more established players.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IPIX Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
IPIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPIX.
Price Targets
Wall Street price target analysis for IPIX.
IPIX MoonshotScore
What does this score mean?
The MoonshotScore rates IPIX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Leo Ehrlich
CEO
Leo Ehrlich has a background in finance and management, with extensive experience in the biopharmaceutical sector. He has held various leadership roles and has been instrumental in guiding Innovation Pharmaceuticals through its transition from Cellceutix Corporation. His educational background includes a focus on business administration, providing him with the skills necessary to navigate the complexities of the pharmaceutical industry.
Track Record: Under Leo Ehrlich's leadership, Innovation Pharmaceuticals has successfully transitioned its brand and focused on developing innovative therapies. His strategic decisions have led to the advancement of key drug candidates and the establishment of valuable partnerships.
IPIX OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher-tier OTC markets or major exchanges like NYSE or NASDAQ. These companies may have limited public information and lower liquidity, making them riskier investments.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can hinder the ability to buy or sell shares without impacting the stock price significantly.
- Regulatory scrutiny may increase, leading to potential compliance challenges.
- Market perception of OTC stocks can lead to undervaluation compared to listed peers.
- Review the company's clinical trial results and progress.
- Evaluate the financial health and funding sources.
- Investigate the management team's track record and experience.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments and potential approval timelines.
- Established partnerships with reputable organizations.
- Active engagement in clinical trials and research.
- Transparency in communications and disclosures.
IPIX Healthcare Stock FAQ
What does Innovation Pharmaceuticals Inc. do?
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for various medical conditions. The company's lead drug candidate, Brilacidin, is in development for multiple indications, including oral mucositis and COVID-19, while Kevetrin is being researched for its potential in treating ovarian cancer.
What are the key growth opportunities for IPIX in healthcare?
Innovation Pharmaceuticals Inc. has several growth opportunities, including the expansion of Brilacidin's applications in treating oral mucositis and COVID-19, which could tap into a market projected to reach $1.2 billion by 2027. Additionally, the advancement of Kevetrin in the oncology market, valued at approximately $4.5 billion, presents significant potential for revenue generation.
What are the main risks for IPIX?
Innovation Pharmaceuticals Inc. faces several risks, including the potential for regulatory approval delays that could impede the commercialization of its drug candidates. Additionally, the company operates in a highly competitive biotechnology landscape, where larger firms may overshadow its efforts. Clinical trial failures pose a significant risk, impacting both the company's financial stability and market reputation.
What are the key factors to evaluate for IPIX?
Innovation Pharmaceuticals Inc. (IPIX) holds an AI score of 39/100 (low). Not financial advice.
How frequently does IPIX data refresh on this page?
IPIX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IPIX's recent stock price performance?
Innovation Pharmaceuticals Inc. (IPIX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with lead candidate Brilacidin targeting multiple diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IPIX overvalued or undervalued right now?
Valuing Innovation Pharmaceuticals Inc. (IPIX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IPIX?
Before investing in Innovation Pharmaceuticals Inc. (IPIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information and may be subject to change.